Abstracts tagged "glucocorticoids"

Abstract Number: 2057 • 2012 ACR/ARHP Annual Meeting
Analysis of the Adherence to the Monitoring of Glucocorticoid Eye Toxicity and of the Prevalence of Cataracts and Glaucoma Among Patients with Systemic Lupus Erythematosus
Linda Carli¹, Chiari Tani¹, Francesca Querci², Alessandra Della Rossa¹, Sabrina Vagnani³, Anna d'Ascanio⁴, Rossella Neri⁵, Antonio Tavoni⁶, Stefano Bombardieri³ and Marta Mosca¹, ¹Internal Medicine, Rheumatology Unit, Department of Internal Medicine, University of Pisa, PISA, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy, ³Department of Internal Medicine, Rheumatology Unit, Department of Internal Medicine, University of Pisa, PISA, Italy, ⁴Department of Internal Medicine, University of Pisa, Rheumatology Unit, Department of Internal Medicine, University of Pisa, PISA, Italy, ⁵University of Pisa, Rheumatology Unit, Pisa, Italy, ⁶Dept of Internal Medicine, Immunoallergology Unit, Department of Internal Meicine, University of Pisa, PISA, Italy
Background/Purpose: Cataracts and glaucoma are among the main causes of impaired visual acuity and have a prevalence respectively of 9-17% and 1-2% among subjects older…
Abstract Number: 1996 • 2012 ACR/ARHP Annual Meeting
Are Changes in Bone Mineral Density Different Between Groups of Early Rheumatoid Arthritis Patients Treated According to a Tight Control Strategy with or without Prednisone, If Osteoporosis Prophylaxis Is Applied?
Marlies C. van der Goes¹, Johannes W.G. Jacobs¹, Maud S. Jurgens¹, Marije F. Bakker¹, Maaike J. van der Veen², Jacobine H. van der Werf³, Paco M.J. Welsing¹ and Johannes W.J. Bijlsma¹, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology, St. Jansdal hospital, Harderwijk, Netherlands, ³Rheumatology, Diakonessenhuis, Utrecht, Netherlands
Background/Purpose: To describe effects on bone mineral density (BMD) of treatment according to EULAR guidelines with a methotrexate-based tight control strategy including 10 mg prednisone…
Abstract Number: 1972 • 2012 ACR/ARHP Annual Meeting
Assessment of Fracture Risk in Postmenopausal Women with Rheumatoid Arthritis
Sina Esmaeilzadeh, Nurten Eskiyurt, Ekin Sen and Merih Akpinar, Physical Medicine and Rehabilitation, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: The aim of this study is to determine the risk of osteoporotic fracture in postmenopausal women with rheumatoid arthritis (RA) and to examine the…
Abstract Number: 1978 • 2012 ACR/ARHP Annual Meeting
A Web-Based Intervention Aimed to Improve Bone Health Among Individuals On Chronic Glucocorticoids
Amy H. Warriner¹, Ryan C. Outman², Nathan Markward³, Ronald Aubert³, Jeffrey R. Curtis⁴, Robert Epstein³, Felix Freuh³, Julia McEachern³, David T. Redden⁵, Monika M. Safford², Eric Stanek³, Amy Steinkellner³ and Kenneth G. Saag⁶, ¹Endocrinology, Diabetes, and Metabolism, The University of Alabama at Birmingham, Birmingham, AL, ²Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Medco, Bethesda, MD, ⁴Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, ⁵Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁶Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL
Background/Purpose: Despite a significant associated fracture risk, previous population-based studies document low osteoporosis treatment rates for individuals treated with chronic glucocorticoids (GCs) at risk for…
Abstract Number: 1946 • 2012 ACR/ARHP Annual Meeting
Effect of Immunosuppressive Treatment On Gene Expression in Patients with Polymyositis and Dermatomyositis
Ingela M. Loell¹, Yi-Wen Chen², Marina Korotkova³, Kanneboyina Nagaraju² and Ingrid E. Lundberg⁴, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ²Center for Genetic Medicine Research, Children's National Medical Center, Washington, DC, ³Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) muscle tissue is characterized by infiltrating T cells, macrophages and dendritic cells, as well as cytokines and chemokines. In…
Abstract Number: 1696 • 2012 ACR/ARHP Annual Meeting
Quantitative Evaluation of Dermal Atrophy by High-Resolution Ultrasonography, Comparing Between Patients Under Long-Term Treatment with Prednisolone or Methylprednisolone
Tim Pottel¹, Christoph Schäfer² and Gernot Keyßer², ¹Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06114 Halle (Saale), Germany, ²Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06120 Halle (Saale), Germany
Background/Purpose: The katabolic effects of a systemic treatment with glucocorticoids can lead to a progressive atrophy of the skin. Clinical observation suggests a more pronounced…
Abstract Number: 1241 • 2012 ACR/ARHP Annual Meeting
Glucocorticoid use Is associated with increase in HDL in Rheumatoid Arthritis Patients
Lisa L. Schroeder¹, Xiaoqin Tang², Mary Chester M. Wasko³ and Androniki Bili⁴, ¹Rheumatology, Geisinger Health System, Danville, PA, ²Biostatistics, Geisinger Center for Health Research, Danville, PA, ³West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, PA, ⁴Rheumatology, Geisinger Medical Center, Danville, PA
Glucocorticoid use is associated with increase in HDL in Rheumatoid Arthritis PatientsBackground/Purpose: Atherogenic lipid profiles are common in active RA, with most common being decreased…
Abstract Number: 1146 • 2012 ACR/ARHP Annual Meeting
Choice of Systemic JIA Treatment Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) Rheumatologists
Jennifer E. Weiss¹, Esi M. Morgan DeWitt², Timothy Beukelman³, Laura E. Schanberg⁴, Rayfel Schneider⁵ and Yukiko Kimura⁶, ¹Pediatric Rheumatology, Hackensack University Medical Center, Hackensack, NJ, ²Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Pediatrics, Duke University Medical Center, Durham, NC, ⁵Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Canada, ⁶Pediatric Rheumatology, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ
Background/Purpose: Despite recent advances in identifying effective treatments for systemic Juvenile Idiopathic Arthritis (sJIA), many pediatric rheumatologists continue to use corticosteroids and methotrexate. The Childhood…
Abstract Number: 469 • 2012 ACR/ARHP Annual Meeting
Intra Articular Injections in Patients with Rheumatoid Arthritis: Analyses From the Behandelstrategiën Study
E. Gvozdenovic¹, L. Dirven¹, M. van den Broek², Kh Han³, T.H.E. Molenaar⁴, R. Landewe⁵, W.F. Lems⁶ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Maasstad hospital, Rotterdam, Netherlands, ⁴Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Intra articular (IA) corticosteroid injections aim at amelioration of symptoms of local inflammation in rheumatoid arthritis (RA). Some patients also report a systemic effect.…
Abstract Number: 389 • 2012 ACR/ARHP Annual Meeting
Oral Glucocorticoid Sparing Effects of Rituximab in Rheumatoid Arthritis Patients Who Have Switched from an Anti-TNF Therapy – an Administrative Claims Database Analysis
Stephen Johnston¹, Tripthi Kamath², Nianwen Shi³, Robert Fowler³, Bong-Chul Chu³ and William Reiss⁴, ¹Truven Health Analytics, Bethesda, MD, ²Genentech, South San Francisco, CA, ³Truven Health Analytics, Washington, DC, ⁴Genentech Inc., South San Francisco, CA
Background/Purpose: The current treatment paradigm in RA is to attempt to decrease concomitant use of oral glucocorticoids (OGC). This study examined the OGC-sparing effects of…
Abstract Number: 367 • 2012 ACR/ARHP Annual Meeting
Improved Fatigue-Related Quality of Life in CAPRA-2, a 12 Week Study of 5-Mg Modified (Delayed) Release Prednisone in Rheumatoid Arthritis
Rieke Alten¹, Amy Grahn², Patricia Rice³ and Frank Buttgereit⁴, ¹Department of Internal Medicine II, Schlosspark-Klinik, University Medicine, Berlin, Germany, ²Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ³Statistics, CliniRx Research, Naperville, IL, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Quality of life in rheumatoid arthritis (RA) patients can be improved by reducing the common symptom of fatigue caused by disease related factors such…
Abstract Number: 2352 • 2012 ACR/ARHP Annual Meeting
Temporal Artery Biopsy Culture in Tridimensional Matrix. an in Vitro Model for Functional Studies in Giant-Cell Arteritis
Marc Corbera Bellalta¹, Ester Planas Rigol¹, Ester Lozano¹, Marco A. Alba², Itziar Tavera-Bahillo¹, Sergio Prieto-González¹, Georgina Espígol Frigolé¹, Montserrat Butjosa¹, José Hernández-Rodríguez¹, Ana García-Martínez³ and Maria C. Cid⁴, ¹Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clinic University Barcelona, Barcelona, Spain, ²Systemic Autoimmune Diseases, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Department of Emergency Medicine, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁴Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: GCA is the most frequent systemic vasculitis in Europe and North America. In spite of the initial response to glucocorticoid treatment more than 60%…
Abstract Number: 228 • 2012 ACR/ARHP Annual Meeting
Simultaneous Initiating of Glucocorticoids and disease-Modifying Antirheumatic Drug Therapy in Polymyositis and Dermatomyositis Patients Results in the Opportunity to Taper Dosage of Glucocorticoids Early
Kavish J. Bhansing¹, Piet LCM Van Riel², Sigrid Pillen³, Baziel G.M. van Engelen⁴ and Madelon C. Vonk⁵, ¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Neurology, Catharina Wilhemina Hospital, Nijmegen, Netherlands, ⁴Neurology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Glucocorticoids are the cornerstone of therapy in patients with polymyositis (PM) and dermatomyositis (DM). However, side effects are common. Furthermore, glucocorticoids exhibits an…
Abstract Number: 2169 • 2012 ACR/ARHP Annual Meeting
Short to Medium Term Safety of Glucocorticoid Therapy in Rheumatoid Arthritis: A Systematic Review and Dose-Response Analysis of Randomized Controlled Trials
Simon Tarp¹, Daniel Furst², John R. Kirwan³, Maarten Boers⁴, Henning Bliddal⁵, Thasia Woodworth⁶, Else Marie Bartels⁷, Bente Danneskiold-Samsoe⁵, Lars Erik Kristensen⁸, Steffen Thirstrup⁹, Mette Rasmussen⁹, Marian Kaldas¹⁰ and Robin Christensen¹, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²Div of Rheumatology, UCLA Medical School, Los Angeles, CA, ³Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, ⁴Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁵Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen F, Denmark, ⁶Leading Edge Clinical Research LLC, Florida, FL, ⁷Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ⁸Rheumatology, Skåen University Hospital, Lund University, Lund, Sweden, ⁹Institute for Pharmacology and Pharmacotherapy, University of Copenhagen, Copenhagen, Denmark, ¹⁰David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, CA
Background/Purpose: Concerns regarding Adverse Effects (AEs) often dominate decisions on applying Glucocorticoid (GC) therapy. Evidence of AEs is mainly based on observational data without proper…
Abstract Number: 50 • 2012 ACR/ARHP Annual Meeting
Human Chondrocyte Dedifferentiation Is Accompagnied by CD105 Endoglin Expression, ALK-1/Smad1/5 Phosphorylation and Leptin Production – Stimulation by Prednisolone and Aldosterone Through the Glucocorticoid Receptor
Olivier Malaise¹, Biserka Relic², Mustapha Zeddou¹, Edith Charlier¹, Florence Quesada Calvo¹, Sophie Neuville³, Dominique de Seny² and Michel G. Malaise⁴, ¹Department of Rheumatology, GIGA Research - University of Liège - CHU Liège, Liège, Belgium, ²Department of Rheumatology, GIGA Research - University of Liège - CHU of Liège, Liège, Belgium, ³GIGA Research - University of Liège - CHU of Liège, Liège, Belgium, ⁴Department of Rheumatology, University of Liège - CHU Liège, Liège, Belgium
Background/Purpose: Leptin, mainly produced by the adipose tissue including fat neighboring the joint, is considered as pro-inflammatory in osteoarthritis (OA). Normal cartilage does not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].